An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients

Trial Profile

An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cryopyrin-associated periodic syndromes
  • Focus Adverse reactions
  • Acronyms B-Confident
  • Sponsors Novartis
  • Most Recent Events

    • 17 Jun 2017 Results (n=68) presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 11 Jun 2016 Final results reporting safety and efficacy from the Beta-Confident Registry presented at the 17th Annual Congress of the European League Against Rheumatism.
    • 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top